解放军医学院学报2018，Vol.39Issue(3)：251-254,4.DOI:10.3969/j.issn.2095-5227.2018.03.018
PD-1/PD-L1抑制剂免疫相关性不良反应及其处理综述
Management of immune-related adverse events of PD-1/PD-L1 inhibitors therapy
摘要
Abstract
Immune checkpoint inhibitors have shown impressive efficacy on malignant tumors and are becoming a mainstay in the treatment of cancer entities. PD-1/PD-L1 inhibitors have been widely used for the treatment of non-small cell lung cancer, malignant melanoma, renal carcinoma and other cancers, and they have prolonged the overall survival of patients. Meanwhile, they can induce immune-related adverse events (irAEs). These side effects can involve any organ and sometimes can be life-threatening. We review the irAEs of PD-1/PD-L1 inhibitors therapy in various organs and the corresponding management, which can provide theory basis for clinical diagnosis and treatment.关键词
免疫检查点抑制剂/免疫治疗/PD-1/PD-L1抑制剂/不良反应Key words
immune checkpoint inhibitor/immunotherapy/PD-1/PD-L1 inhibitor/adverse reaction分类
医药卫生引用本文复制引用
刘甜,胡毅..PD-1/PD-L1抑制剂免疫相关性不良反应及其处理综述[J].解放军医学院学报,2018,39(3):251-254,4.基金项目
国家自然科学基金项目(81672996) （81672996）
Supported by the National Natural Science Foundation of China (81672996) （81672996）
